Publicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (20)

2023

  1. Guided Genioplasty: Comparison between Conventional Technique and Customized Guided Surgery

    Journal of Personalized Medicine, Vol. 13, Núm. 12

2022

  1. Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases

    Cancers, Vol. 14, Núm. 5

  2. Histopathology of Dermatologic Complications of Tattoos

    American Journal of Dermatopathology, Vol. 44, Núm. 9, pp. 632-649

  3. Metataxonomic Analysis of Milk Samples From SARS-CoV-2-Positive and SARS-CoV-2-Negative Women

    Frontiers in Nutrition, Vol. 9

  4. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

  5. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64

2021

  1. Immediate Pre-Partum SARS-CoV-2 Status and Immune Profiling of Breastmilk: A Case-Control Study

    Frontiers in Immunology, Vol. 12

  2. Mother's Bed Incline and Desaturation Episodes in Healthy Term Newborns during Early Skin-to-Skin Contact: A Multicenter Randomized Controlled Trial

    Neonatology, Vol. 118, Núm. 6, pp. 702-709

  3. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

    Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2

2020

  1. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

    Future Oncology, Vol. 15, Núm. 17, pp. 1951-1961

2018

  1. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

    The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824

  2. Tecnologías de la Información y la Comunicación (TIC): abuso de Internet, videojuegos, teléfonos móviles, mensajería instantánea y redes sociales mediante el MULTICAGE-TIC

    Adicciones: Revista de socidrogalcohol, Vol. 30, Núm. 1, pp. 19-32

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

2015

  1. Exercise triggers ARVC phenotype in mice expressing a disease-causing mutated version of human plakophilin-2

    Journal of the American College of Cardiology, Vol. 65, Núm. 14, pp. 1438-1450

2014

  1. A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21 WAF1/CIP1 ) Degradation

    PLoS Genetics, Vol. 10, Núm. 10

  2. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer

    Journal of Clinical Oncology, Vol. 32, Núm. 32, pp. 3626-3634

  3. β3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes

    Basic Research in Cardiology, Vol. 109, Núm. 4

2013

  1. Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas

    PLoS ONE, Vol. 8, Núm. 6